MannKind is no longer only a royalty collector sitting under United Therapeutics. The second quarter delivered the three catalysts management had framed as the year's test: pediatric approval for Afrezza, approval of the Furoscix ReadyFlow autoinjector, and a clean Phase 1b readout for inhaled nintedanib. Those events recast the equity as a commercial-execution story rather than a single-partner cash-flow story. The debate is whether owned products can grow fast enough to justify the launch spend and the Blackstone-funded scPharma purchase, or whether the company remains a high-cost satellite of Tyvaso DPI. Second-quarter revenue reached $109 million on that mix shift.
The load-bearing change is the mix, not the headline. Marketed Afrezza and Furoscix sales rose sequentially and, for the first time, outpaced the royalty line as a share of underlying product economics. Furoscix contributed $22 million of net sales. Afrezza printed $17 million even as the adult franchise was de-emphasized ahead of the pediatric launch. United Therapeutics still supplied most of the rest through manufacturing and a high-single-digit net royalty on Tyvaso DPI. Selling, general and administrative expense nearly doubled as field teams were built for two launches, and reported results swung back into a loss.
Gross margin on commercial products compressed because Furoscix carries a heavier cost structure than inhaled insulin. A mid-twenty-percent gross-to-net drag also offset strong unit growth. Cash and investments stood near $111 million at mid-year. A subsequent $50 million private placement largely funds the ReadyFlow contingent-value-right payout. Shares trade in the mid-three range against an equity value just above $1 billion. The next several quarters resolve whether ReadyFlow mix, pediatric refill, and a still-growing Tyvaso franchise can convert this investment year into owned-revenue scale.